Publications by authors named "Pei-Hsuan Ye"
Article Synopsis
- * JTC-801, an opioid peptide antagonist, and sodium oxamate, a glycolysis inhibitor, have not been fully explored in TNBC treatments, but their combination may produce synergistic anticancer effects.
- * In experiments with the MDA MB-231 TNBC cell line, the co-treatment of JTC-801 and sodium oxamate resulted in significant cell death and tumor suppression, indicating a promising new therapeutic approach for TNBC patients.
Article Synopsis
- Tumor progression is influenced by both tumor cells and their surrounding microenvironment, so effective cancer therapies should target cancer cells while also boosting immune cell activity.* -
- Arginine modulation plays a crucial role in cancer treatment; arginase inhibitors can activate T-cells by increasing arginine levels, while agents like ADI-PEG 20 deplete arginine in certain tumor cells, leading to an anti-tumor effect without harming normal immune cells.* -
- Combining an arginase inhibitor (L-Norvaline) with ADI-PEG 20 shows promise in enhancing anti-tumor responses, particularly in melanoma, by increasing CD8 T cell infiltration and reducing immunosuppressive cell populations,
Background: Nitric oxide-releasing drugs are used for cardiovascular diseases; however, their effects on the tumor immune microenvironment are less clear. Therefore, this study explored the impact of nitric oxide donors on tumor progression in immune-competent mice.
Methods: The effects of three different nitric oxide-releasing compounds (SNAP, SNP, and ISMN) on tumor growth were studied in tumor-bearing mouse models.